Drugs / ZOSURABALPIN
ZOSURABALPIN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05614895 | Dec 2022 → Jan 2024 | bacterial infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04605718 | Dec 2020 → Mar 2023 | — | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZOSURABALPIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314563 ↗ |
| Known as | RG-6006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314563 ↗ |
| Known as | RO7223280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04605718 ↗ |
| Known as | Zosurabalpina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314563 ↗ |
| Known as | Zosurabalpine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314563 ↗ |
| Modality | Small molecule | — CHEMBL5314563 ↗ |
| Route | Intravenous | “RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg” NCT04605718 ↗ |